HC Wainwright Has Pessimistic Outlook of MRKR Q3 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – HC Wainwright lowered their Q3 2026 EPS estimates for shares of Marker Therapeutics in a research note issued on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now expects that the company will earn ($0.25) per share for the quarter, down from their prior estimate of ($0.24). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Marker Therapeutics’ FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.34) EPS and FY2028 earnings at ($1.02) EPS.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $10.00.

Marker Therapeutics Trading Up 1.4%

MRKR stock opened at $1.41 on Thursday. The company has a market cap of $23.50 million, a price-to-earnings ratio of -2.31 and a beta of 1.43. Marker Therapeutics has a 12 month low of $0.81 and a 12 month high of $4.07. The firm has a 50-day moving average of $1.44 and a two-hundred day moving average of $1.44.

Marker Therapeutics (NASDAQ:MRKR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.78 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%.

Institutional Trading of Marker Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new stake in shares of Marker Therapeutics during the 2nd quarter worth approximately $33,000. Virtu Financial LLC acquired a new stake in shares of Marker Therapeutics during the 3rd quarter worth approximately $25,000. Two Sigma Investments LP acquired a new stake in shares of Marker Therapeutics during the 3rd quarter worth approximately $33,000. Boyer Financial Services Inc. acquired a new stake in shares of Marker Therapeutics during the 4th quarter worth approximately $57,000. Finally, XTX Topco Ltd increased its holdings in shares of Marker Therapeutics by 166.6% during the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after buying an additional 36,269 shares during the last quarter. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics News Roundup

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: Zacks upgraded Marker Therapeutics (MRKR) to a Buy rating, signaling stronger earnings optimism and a potentially supportive near-term catalyst. Article Title
• Positive Sentiment: Brookline Capital Markets raised its FY2027 and FY2030 earnings estimates for Marker Therapeutics, reinforcing a longer-term growth narrative.
• Positive Sentiment: The company’s FY2026 earnings estimate was slightly improved by Brookline Capital Markets, a small but favorable adjustment to near-term expectations.
• Neutral Sentiment: Marker Therapeutics announced the date for its 2026 annual meeting, a routine update that is unlikely to materially affect the stock on its own. Article Title
• Negative Sentiment: Brookline cut some quarterly and out-year EPS forecasts, including Q2 and Q3 2026 and FY2028/FY2029, highlighting ongoing uncertainty around the company’s path to profitability.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.